BMC Cancer by Park, Hannah Lui et al.
RESEARCH ARTICLE Open Access
Novel polymorphisms in caspase-8 are
associated with breast cancer risk in the
California Teachers Study
Hannah Lui Park1*, Argyrios Ziogas1, Jenny Chang1, Bhumi Desai1, Leona Bessonova1, Chad Garner1, Eunjung Lee2,
Susan L. Neuhausen3, Sophia S. Wang3, Huiyan Ma3, Jessica Clague3, Peggy Reynolds4, James V. Lacey Jr3,
Leslie Bernstein3 and Hoda Anton-Culver1
Abstract
Background: The ability of tamoxifen and raloxifene to decrease breast cancer risk varies among different breast
cancer subtypes. It is important to determine one’s subtype-specific breast cancer risk when considering
chemoprevention. A number of single nucleotide polymorphisms (SNPs), including one in caspase-8 (CASP8),
have been previously associated with risk of developing breast cancer. Because caspase-8 is an important
protein involved in receptor-mediated apoptosis whose activity is affected by estrogen, we hypothesized that
additional SNPs in CASP8 could be associated with breast cancer risk, perhaps in a subtype-specific manner.
Methods: Twelve tagging SNPs of CASP8 were analyzed in a nested case control study (1,353 cases and 1,384
controls) of non-Hispanic white women participating in the California Teachers Study. Odds ratios (ORs) and 95 %
confidence intervals (CIs) were calculated for each SNP using all, estrogen receptor (ER)-positive, ER-negative, human
epidermal growth factor receptor 2 (HER2)-positive, and HER2-negative breast cancers as separate outcomes.
Results: Several SNPs were associated with all, ER-positive, and HER2-positive breast cancers; however, after correcting
for multiple comparisons (i.e., p < 0.0008), only rs2293554 was statistically significantly associated with HER2-positive
breast cancer (OR = 1.98, 95 % CI 1.34-2.92, uncorrected p = 0.0005).
Conclusions: While our results for CASP8 SNPs should be validated in other cohorts with subtype-specific information,
we conclude that some SNPs in CASP8 are associated with subtype-specific breast cancer risk. This study contributes to
our understanding of CASP8 SNPs and breast cancer risk by subtype.
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Background
Breast cancer risk factors include a woman’s age, family
history, reproductive and gynecologic factors, and life-
style factors including alcohol consumption and lack of
physical activity [1]. When treating women at high risk for
breast cancer, clinicians may recommend that women
undergo increased screening, genetic testing, or chemo-
prevention [2–4]. Phase III breast cancer chemopre-
vention trials have now demonstrated the efficacy of
selective estrogen receptor (ER) modulators (SERMs)
(e.g., tamoxifen and raloxifene) and aromatase inhibi-
tors in reducing the incidence of breast cancer. How-
ever, these drugs were significantly more effective at
reducing the incidence of ER-positive breast cancer
than ER-negative breast cancer [5–13]. ER-positivity is
also associated with better prognosis after breast cancer
diagnosis than ER-negativity [14, 15], while human epider-
mal growth factor receptor 2 (HER2)-positivity [16] and
triple negativity (ER-negative, progesterone receptor (PR)-
negative, and HER2-negative) [17] are each associated
with worse prognosis. Drugs to target prevention of
HER2-positive breast cancer and triple-negative breast
cancers are also currently being studied [18]. With known
undesirable side effects associated with chemopreventive
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medications that have been developed thus far, knowledge
of one’s risk not only for any breast cancer but for specific
subtypes of breast cancer would be helpful for a woman
and her physician when considering chemopreventive
therapy options.
Breast cancer risk models currently used by clinicians
to identify women at high risk of developing breast can-
cer exhibit limited sensitivities and specificities [1]; and
many studies have focused on identifying genetic vari-
ation associated with breast cancer risk with the hope
that single nucleotide polymorphism (SNP) genotyping
can be used to better stratify breast cancer risk and
inform clinical management. While it is known that mu-
tations in BRCA1 and BRCA2 markedly increase one’s
risk of developing breast cancer [19, 20], a number of
additional low and moderate-risk susceptibility variants
have been identified, including one for caspase-8 (CASP8),
an enzyme involved in apoptosis [21].
Caspase-8 is activated in response to extrinsic apop-
totic signals, including chemotherapy agents [22]. In
vitro, estrogen inhibits caspase-8 activity and activity of
other caspases [23]. The Breast Cancer Association
Consortium (BCAC) has identified 3 SNPs in CASP8,
namely rs1045485, rs17468277, and rs1830298, which
are associated with breast cancer risk [24–26]. Other
CASP8 SNPs have shown to be associated with increased
breast cancer risk [27–29]. Besides two BCAC studies,
which found that rs1045485 was associated with a lower
risk of PR-positive breast cancer [25], rs1830298 was
associated with higher risk of ER-positive and triple-
negative breast cancer [26], and rs36043647 was associ-
ated with lower risk of overall, ER-positive, ER-negative,
and triple negative breast cancer [26], few studies have
described associations between CASP8 polymorphisms
and subtype-specific breast cancer risk. Given the im-
portant role of caspase-8 in apoptosis, we hypothesized
that additional CASP8 polymorphisms would be associ-
ated with breast cancer risk and that the associations
might be specific to some breast cancer subtypes. The
aim of this study was to examine potential associations
between 12 CASP8 polymorphisms and breast cancer
risk, overall and by subtype, using case and control sam-
ples nested within the California Teachers Study (CTS).
Methods
Ethics statement
This study was carried out in compliance with the
Helsinki Declaration and approved by the Institutional Re-
view Boards at each study center, namely, the City of Hope
(COH), the University of Southern California (USC), the
Cancer Prevention Institute of California (CPIC), the Uni-
versity of California at Irvine (UCI), and by the California
State Committee for the Protection of Human Subjects, in
accordance with assurances filed with and approved by
the US Department of Health and Human Services. All
study participants provided written informed consent to
participate in the study.
Participants
The CTS is a well-established prospective cohort study
of 133,479 female California public school teachers and
administrators who were enrolled in the California State
Teachers Retirement System. A detailed account of the
methods employed by the CTS has been published pre-
viously [30]. Briefly, participants completed a baseline
questionnaire and returned it by mail in 1995–1996. The
baseline survey, which collected information on demo-
graphics, personal and family cancer history, height,
weight, history of hormone use, and behavioral factors
including physical activity and alcohol consumption, is
available on the CTS website (www.calteachersstudy.org).
New diagnoses of first primary invasive breast cancer
among cohort members were identified through annual
linkages with California Cancer Registry (CCR), a legally
mandated statewide population-based cancer reporting
system in which cancer data are obtained from cancer
patients’ pathology reports at the hospital in which the pa-
tient was initially diagnosed. CCR ascertainment of newly
diagnosed cancers is estimated to be 99 % complete [31].
For this nested, breast cancer case control study, biospe-
cimens were collected between 2005-2009 from breast
cancer cases diagnosed under age 80 years and unaffected
controls in the cohort, all of whom had continued resi-
dence in California during the study period (1995 to time
of blood draw). Cases were women who had a histologi-
cally confirmed invasive first primary carcinoma of the
breast (International Classification of Disease for Oncol-
ogy code C50 restricted to morphology codes under 8590)
after 1998. Unaffected control participants were selected
from the cohort and frequency matched to the cases based
on age at baseline (within 5-year age groups), self-
reported race/ethnicity (white, African American, Latina,
Asian, and other), and three broad geographic regions in
California (surrounding the three CTS specimen collec-
tion centers: CPIC, USC/COH, and UCI).
Collection of biological specimens and DNA extraction
The collection of specimens has been described previously
[32]. Briefly, cases and controls provided a blood sample
and completed a brief questionnaire at the time of blood
draw, which updated breast and reproductive and gyneco-
logic history and several lifestyle factors. Women who
declined providing blood provided saliva in Oragene DNA
self-collection kits (DNA Genotek, Kanata, ON, Canada).
All biological specimens were sent overnight to the UCI
laboratory. DNA was extracted from blood clots using
Qiagen Clotspin Baskets and DNA QIAmp DNA Blood
Maxi Kits (Qiagen, Inc., Valencia, CA, USA) in accordance
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with Qiagen protocols. DNA was extracted from saliva
samples using the Oragene protocol (DNA Genotek).
Genotyping
The 12 tagging SNPs included in this analysis were se-
lected to capture all common linkage disequilibrium tag-
ging SNPs [minor allele frequency (MAF) of at least 5
%], 20 kb upstream of the 5' untranslated region (UTR)
and 10 kb downstream of the 3' UTR, in individuals of
European ancestry with minimum pairwise r2 of at least
0.80, using data from the International HapMap Project
for the white CEPH (Utah residents with ancestry from
northern and western Europe) population [HapMap re-
lease 21, July 2006, genotype build 36 (http://hapmap.nc-
bi.nlm.nih.gov)] [32].
DNA samples from 1,751 cases and 1,697 controls were
plated for genotyping. A random sample of 193 duplicates
(105 cases and 88 controls) was included for quality con-
trol. The samples were genotyped using the Illumina
Golden Gate Assay (Illumina, Inc., San Diego, CA USA) at
the University of Southern California Core Facility. Twelve
haplotype-tagging SNPs in CASP8 were included and
genotyped. Samples with genotype call rates <90 % were
excluded. Among the remaining samples, 160 randomly
selected duplicates exhibited a genotype concordance rate
of 99.9 %. Additional details were described previously
[32]. Because the majority of participants were non-
Hispanic whites, we restricted analyses to 2,737 non-
Hispanic white women (1,353 cases and 1,384 controls).
Statistical analyses
All statistical tests were two-sided. We used uncondi-
tional logistic regression models to estimate the odds
ratios (ORs), 95 % confidence intervals (CIs), and p-
values for the association of invasive breast cancer and
each SNP, using log-additive models. Allele frequencies
are shown in Additional file 1: Table S1. We adjusted for
potential confounding by study center and other known
risk factors, namely, age at baseline, family history (hav-
ing a first-degree relative with history of breast cancer),
body mass index (<25, 25.0-29.9, ≥30 kg/m2), alcohol
consumption in the past year (none, <20 g/day, ≥20 g/
day), physical activity in the past 3 years (0-0.5 hrs/wk/
yr, 0.51–4.0 hr/wk/yr, >4.0 hr/wk/yr), and menopausal
and hormone therapy (HT) status (premenopausal, post-
menopausal and never used HT, postmenopausal and
used HT in the past, postmenopausal and using estrogen
only at baseline, postmenopausal and using estrogen and
progesterone at baseline, and unknown) at baseline. To po-
tentially improve power by increasing subgroup homogen-
eity, we stratified our analysis by estrogen receptor (ER)
and human epidermal receptor (HER2) status of breast
cancer. We evaluated the association for ER-positive (n =
1,046), ER-negative (n = 155), HER2-positive (n = 159), and
HER2-negative (n = 662) subtype. Some breast cancers were
not included in any specific receptor (ER or HER2) subtype
analysis because they were missing either ER or HER2 sta-
tus. PR status was not included since PR expression usually
follows ER expression [33] and the clinical rationale to de-
termine associations with PR-specific breast cancer risk was
lacking since no chemotherapies or preventive therapies are
being studied for PR status-specific subtypes. While therap-
ies targeting triple-negative breast cancer are being consid-
ered, the number of triple-negative cancers in our subset of
cases and controls was too small for analysis (n = 60). We
used the conservative Bonferroni correction to correct for
multiple testing (n = 60, 12 SNPs x 5 outcomes). Statistical
significance was set to p < 0.0008. All analyses were done
using SAS software version 9.2.
Recombination rates and linkage disequilibrium across
the CASP8 gene was evaluated using the HapMap data-
base (http://hapmap.ncbi.nlm.nih.gov) and r2 values were
computed from the pairwise SNP genotype counts of the
generated genotype data.
Results
Baseline characteristics of the cases and controls are
provided in Table 1. Consistent with other studies, fam-
ily history of breast cancer, menopause and hormone
therapy (HT) use, physical inactivity, and alcohol use
were associated with breast cancer risk. Genotype distri-
butions are provided in Additional file 1: Table S1.
CASP8 polymorphisms and invasive breast cancer risk
The adjusted ORs and 95 % CIs of overall invasive breast
cancer with CASP8 polymorphisms are shown in Table 2.
Four SNPs had a p-value < 0.05 for positive associations
with overall breast cancer (rs11899004, rs3769825,
rs6723097 and rs6736233). The SNP most strongly asso-
ciated with overall breast cancer risk was rs6736233,
which conferred an OR of 1.38 (95 % CI 1.12-1.71, p =
0.0028) (Table 2). After correcting for multiple compari-
sons, none of the SNPs tested remained statistically sig-
nificant at p < 0.0008.
When ER-positive and ER-negative breast cancer out-
comes were analyzed separately, the trends of increased risk
with rs3769825, rs6723097 and rs6736233 as seen for
overall breast cancer remained for ER-positive breast
cancers (Table 3). However, after correcting for mul-
tiple comparisons, none of the associations remained
statistically significant. None of the SNPs tested were
associated with ER-negative breast cancer risk.
Three of the four SNPs that were associated with overall
invasive breast cancer (p value < 0.05) were associated
with HER2-positive invasive breast cancer (rs11899004,
rs6723097, and rs6736233). rs2293554 was also associ-
ated with HER2-positive invasive breast cancer (OR =
1.98, 95 % CI 1.34-2.92, uncorrected p = 0.0005). After
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correcting for multiple comparisons, rs2293554 was
the only SNP that remained statistically significant.
Two of the four SNPs that were associated with over-
all invasive breast cancer (p value < 0.05) were associ-
ated with HER2-negative invasive breast cancer
(rs3769825 and rs6723097). However, after correcting
for multiple comparisons, neither remained statisti-
cally significant (Table 4).
In summary, after correction for multiple testing, one of
the twelve CASP8 SNPs tested in our study remained
nominally statistically significantly associated with invasive
breast cancer, specifically, HER2-positive breast cancer.
Table 1 Selected baseline characteristics of study participants by case (invasive breast cancer) and control status
Variables Cases (n = 1353) % Controls (n = 1384) % Chi square p-value
Age, years (mean ± SD) 55.0 ± 9.4 56.1 ± 9.5
First-degree family history of breast cancer 0.0046
No 1086 80.3 1158 83.7
Yes 237 17.5 187 13.5
Body mass index, kg/m2 0.21
< 25 779 57.6 759 54.8
25 to 29.9 384 28.4 385 27.8
≥ 30 160 11.8 192 13.9
Age at menarche, years 0.45
< 13 700 51.7 695 50.2
≥ 13 638 47.2 671 48.5
Parity 0.12
0 289 21.4 280 20.2
1 173 12.8 165 11.9
2 481 35.6 476 34.4
3 275 20.3 277 20.0
≥ 4 120 8.9 165 11.9
Age at first full-term pregnancy, years 0.38
< 21 89 8.5 96 8.9
21-24 325 31.0 343 31.7
25-29 415 39.6 451 41.6
30-34 169 16.1 155 14.3
≥ 35 51 4.9 38 3.5
Hormone therapy (HT) at baseline 0.0001
Premenopausal 364 26.9 346 25.0
Postmenopausal - never used HT 113 8.4 150 10.8
Postmenopausal - past use HT 76 5.6 115 8.3
Postmenopausal - current estrogen use 200 14.8 249 18.0
Postmenopausal - current estrogen + progestin use 402 29.7 335 24.2
Unknown 198 14.6 189 13.7
Strenuous or moderate physical activity, during 3 years before baseline 0.0035
0-0.50 hrs/week/year 290 21.4 289 20.9
0.51-4.00 hrs/week/year 632 46.7 572 41.3
4.01-24 hrs/week/year 424 31.3 514 37.1
Grams per day of alcohol, during year before baseline 0.0006
Nondrinkers 334 24.7 379 27.4
< 20 g/d 806 59.6 836 60.4
> =20 g/d 165 12.2 109 7.9
Table does not list small percentages of missing values for some factors
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Linkage disequilibrium
An analysis of data from the HapMap database indicated
that very low historical genetic recombination exists
across the entire CASP8 gene in individuals of European
descent, with pairwise D’ values near 1.0 for all SNP pairs
spanning the gene in the database. The alleles at the five
markers that were associated with breast cancer risk in
this study before correcting for multiple comparisons
were not strongly correlated, as measured by the linkage
disequilibrium measure r2. This low correlation (r2) in the
context of high linkage disequilibrium (D’) was expected
given that the SNPs were selected as tagging markers.
Three pairs of SNPs showed r2values greater than 0.4:
r2 = 0.44 for rs11899004 and rs2293554; r2 = 0.52 for
rs11899004 and rs6736233; and r2 = 0.45 for rs3769825
and rs6723097. The remaining pairwise r2 values were all












OR 95 % CI p** OR 95 % CI p**
rs12693932 202093395 C T 0.47 1.042 0.936 1.160 1.050 0.950 1.180
rs6745051 202108741 C A 0.48 1.039 0.933 1.156 1.050 0.940 1.170
rs3769825 202111380 G A 0.45 1.097 0.986 1.219 1.120 1.010 1.250 0.034
rs11899004 202114026 G A 0.14 1.162 1.002 1.348 0.048 1.170 1.010 1.360 0.041
rs6736233 202118974 G C 0.06 1.367 1.111 1.682 0.003 1.380 1.120 1.710 0.003
rs1861270 202126615 G A 0.27 1.036 0.921 1.164 1.070 0.950 1.200
rs6723097 202128618 C A 0.38 1.131 1.015 1.259 0.026 1.170 1.050 1.310 0.005
rs2293554 202131587 T G 0.07 1.164 0.950 1.427 1.190 0.970 1.470
rs1045485 202149589 G C 0.11 1.036 0.875 1.226 1.020 0.860 1.210
rs1035140 202152491 A T 0.46 1.030 0.927 1.143 1.050 0.940 1.170
rs700636 202153252 C A 0.43 1.051 0.944 1.169 1.080 0.970 1.210
rs11679181 202162338 C T 0.44 0.944 0.848 1.050 0.920 0.830 1.030
aPer-allele ORs. Models were adjusted for center, age, family history, BMI, recent physical activity, alcohol consumption, and menopause/HT status
**Only uncorrected p values <0.05 are listed
Table 3 Multivariate adjusted odds ratios (OR) and 95 % confidence intervals (CI) of ER-positive and ER-negative invasive breast can-
cer associated with caspase-8 polymorphisms
SNP ER-positive ER-negative
Unadjusted Adjusteda Unadjusted Adjusteda
OR 95 % CI p** ORa 95 % CI p** OR 95 % CI p** ORa 95 % CI p**
rs12693932 1.075 0.957 1.207 1.090 0.970 1.220 1.013 0.800 1.282 1.010 0.800 1.290
rs6745051 1.072 0.955 1.203 1.080 0.960 1.220 0.994 0.784 1.259 0.990 0.780 1.260
rs3769825 1.108 0.989 1.242 1.130 1.010 1.270 0.035 1.107 0.876 1.398 1.140 0.900 1.440
rs11899004 1.160 0.990 1.358 1.170 1.000 1.380 1.029 0.734 1.443 1.030 0.730 1.460
rs6736233 1.364 1.096 1.697 0.005 1.360 1.090 1.710 0.006 1.180 0.740 1.882 1.260 0.780 2.020
rs1861270 1.038 0.914 1.178 1.070 0.940 1.210 1.066 0.824 1.379 1.110 0.860 1.450
rs6723097 1.123 0.999 1.262 1.160 1.030 1.310 0.014 1.089 0.859 1.381 1.150 0.900 1.460
rs2293554 1.137 0.915 1.413 1.170 0.930 1.460 1.162 0.747 1.806 1.210 0.770 1.900
rs1045485 1.088 0.911 1.300 1.060 0.890 1.270 0.942 0.638 1.391 0.940 0.630 1.400
rs1035140 1.025 0.916 1.147 1.040 0.930 1.170 1.028 0.815 1.297 1.080 0.860 1.370
rs700636 1.021 0.910 1.144 1.050 0.940 1.180 1.046 0.828 1.322 1.100 0.870 1.400
rs11679181 0.955 0.851 1.071 0.940 0.840 1.060 0.978 0.772 1.238 0.920 0.720 1.170
aPer-allele ORs. Models were adjusted for center, age, family history, BMI, recent physical activity, alcohol consumption, and menopause/HT status
**Only uncorrected p values <0.05 are listed
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less than 0.2. rs6723097 and rs6736233 were the two SNPs
most significantly associated with breast cancer risk over-
all, with uncorrected p-values of 0.0053 and 0.0028, re-
spectively. These two SNPs are uncorrelated (r2 = 0.07)
and likely represent independent associations.
Discussion
This study is the first to identify the CASP8 SNP,
rs2293554, to be statistically significantly associated with
HER2-positive breast cancer risk in non-Hispanic white
women. In our study, the observed OR of 1.98 with 95 %
confidence interval of 1.34–2.92 for HER2-positive
breast cancer risk was surprisingly high, especially given
the small number of HER2-positive breast cancers in
our study. It is possible that the observation may have
been due to chance. A previous study reported that
rs2293554 was not associated with breast cancer risk
overall [34], similar to what we observed here; however,
subtype-specific breast cancers were not evaluated in
that study.
The most recent BCAC paper on CASP8 [26] covered
the analysis of 501 typed and 1232 imputed SNPs, and,
while some CTS samples were included in the BCAC
study, there was only overlap of 57 triple-negative and 49
controls between the BCAC study and our present ana-
lysis. rs2293554 was not included on the panel of CASP8
SNPs analyzed in the BCAC paper [26]; however,
using the SNP lookup function on the BCAC website
(http://apps.ccge.medschl.cam.ac.uk/consortia/bcac), we
found that rs2293554 was not associated with overall, ER
+, or ER- breast cancer risk. Data for HER2-specific breast
cancer risk were not available on the website, but
through personal email communication with the
BCAC Data Manager, we learned that the BCAC data
indicated that there was not an association between
rs2293554 and HER2-positive breast cancer risk.
rs2293554 was in strong LD with 16 of the 109 SNPs
identified in the BCAC paper to be associated with overall
breast cancer risk with FDR < 0.05 [26], with r2 > 0.50, ac-
cording to the Linkage Disequilibrium Calculator (https://
caprica.genetics.kcl.ac.uk/~ilori/ld_calculator.php), using
the European panel in the 1000 genomes project;
however, their effects were in the opposite direction
(Additional file 2: Table S2). While our observation
was not consistent with those in the BCAC study, our data
demonstrates that SNPs can have different associations
with breast cancer risk according to subtype and that
rs2293554, with its nominally significant association with
HER2-positive breast cancer risk in the CTS cohort,
warrants further investigation.
Our study confirmed results from a meta-analysis,
in which rs6723097 was associated with increased
breast cancer risk [OR = 1.16 (95 % CI 1.07–1.25)]
[34], and from a separate study [OR = 1.15 (95 %
CI 1.01–1.30)] [27]. Here, the observed OR was 1.17
(95 % CI 1.05–1.31). Also consistent with previous
studies, no associations with breast cancer risk were
found for rs1035140 [34] and rs1861270 [27]. Eleven
of the 12 SNPs analyzed in our study were included
in a recent fine-mapping analysis by the BCAC [26].
Their findings were consistent with ours in that the 11
SNPs were not statistically significant after adjusting
Table 4 Multivariate adjusted odds ratios (OR) and 95 % confidence intervals (CI) of HER2-positive and HER2-negative invasive
cancer associated with caspase-8 polymorphisms
SNP HER2-positive HER2-negative
Unadjusted Adjusteda Unadjusted Adjusteda
OR 95 % CI p** OR* 95 % CI p** OR 95 % CI p** OR* 95 % CI p**
rs12693932 1.111 0.879 1.404 1.110 0.870 1.410 1.123 0.983 1.281 1.150 1.000 1.320
rs6745051 1.148 0.908 1.450 1.150 0.900 1.460 1.095 0.959 1.249 1.120 0.980 1.280
rs3769825 1.153 0.915 1.455 1.180 0.930 1.490 1.164 1.020 1.327 0.024 1.200 1.050 1.370 0.008
rs11899004 1.680 1.259 2.241 0.0004 1.620 1.210 2.180 0.0014 1.118 0.930 1.344 1.130 0.940 1.360
rs6736233 1.959 1.332 2.881 0.001 1.890 1.270 2.810 0.0017 1.283 0.995 1.655 1.290 0.990 1.670
rs1861270 0.983 0.758 1.275 1.050 0.800 1.370 1.098 0.952 1.268 1.150 0.990 1.330
rs6723097 1.336 1.057 1.688 0.015 1.410 1.110 1.800 0.0055 1.170 1.025 1.337 0.020 1.220 1.070 1.400 0.004
rs2293554 1.945 1.341 2.822 0.001 1.980 1.340 2.920 0.0005 1.165 0.910 1.490 1.200 0.930 1.550
rs1045485 0.852 0.572 1.268 0.810 0.540 1.220 1.072 0.872 1.317 1.030 0.830 1.270
rs1035140 0.958 0.760 1.207 1.000 0.790 1.270 1.081 0.950 1.231 1.100 0.970 1.260
rs700636 1.012 0.802 1.276 1.080 0.850 1.380 1.076 0.944 1.226 1.110 0.970 1.270
rs1679181 1.048 0.831 1.323 0.990 0.780 1.260 0.910 0.798 1.039 0.890 0.780 1.020
aPer-allele ORs. Models were adjusted for center, age, family history, BMI, recent physical activity, alcohol consumption, and menopause/HT status
**Only uncorrected p values <0.05 are listed; after correcting for multiple comparisons, only rs2293554 was statistically significantly associated with HER2-positive
breast cancer risk
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for multiple comparisons, or, in the case of the other
paper, genome-wide significance of P = 5 x 10-8. The re-
sults for these SNPs were not shown by receptor subtype.
To correct for multiple testing, we used Bonferroni adjust-
ment, which is very conservative, since the SNPs and phe-
notypes we tested were somewhat correlated. Given the
importance of replicating genetic associations [35], our
study, conducted in a well-established, well-characterized
prospective cohort [30] contributes important information
on the relationship between CASP8 polymorphisms and
breast cancer risk.
Our results for rs1045485 were not consistent with
those from two meta-analyses, which reported inverse
associations with breast cancer, with pooled ORs of 0.87
(95 % CI 0.83-0.92) [28] and 0.79 (95 % CI 0.69-0.92)
[29]. Our findings are consistent with a number of inde-
pendent studies on the same SNP, some of which were
included in the meta-analyses [28, 29] and a separate
study [34] in which no association was found between
this SNP and breast cancer risk. The MAF (10.5 % ) we
observed in this study (all non-Hispanic Whites) is simi-
lar to that seen in the women of European ancestry [10,
35]. One of the BCAC studies on CASP8, which involved
>30,000 invasive breast tumors, showed that rs1045485
was most strongly related with the risk of PR-negative
tumors [25], but an association was not replicated in a
later BCAC study [26]. Because no reports of develop-
ment of PR status-specific chemoprevention were found
at the time of the study, PR-specific subtypes were not
included as outcomes in this study.
While the polymorphic CASP8 sites identified in
this study are all intronic, it is possible that they
may affect expression of the protein or RNA spli-
cing, which may affect protein-protein interactions
and other functions. rs6723097 and rs6736233 were
found to have features consistent with involvement
in gene transcription regulation according to the
Variant Effect Predictor (VEP) on the Ensembl website
(http://uswest.ensembl.org/Homo_sapiens/Tools/VEP)
[36]. The other SNPs we found to be associated with breast
cancer risk did not have such features. However, rs12693932
and rs6745051 are in strong LD with each other, and they
are also in strong LD with the SNP rs13006529, which is a
missense, according to the University of Washington Gen-
ome Variation Server (http://gvs.gs.washington.edu/GVS144/).
Also, rs1861270 is in strong LD with the SNP rs3769823,
which is also a missense. Neither rs13006529 nor rs3769823
have been reported to be associated with breast cancer
risk. The remaining SNPs on our panel are not in LD with
other SNPs with known functions.
Conclusions
We conclude that the CASP8 SNP, rs2293554, is nomin-
ally statistically significantly associated with HER2-
positive breast cancer risk in non-Hispanic white
women, even after stringent correction for multiple
comparisons. Other CASP8 SNPs were also associated
with overall, ER-positive, and HER2-negative breast can-
cer risk but the associations were not statistically signifi-
cant after correction. While our results should be
validated in other cohorts with subtype-specific informa-
tion, this study contributes to our understanding of
CASP8 SNPs and subtype-specific breast cancer risk.
The mechanistic and functional consequences of CASP8
SNPs in breast cancer development and their relevance
in women of other racial/ethnic groups remain to be
investigated.
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